What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Archive — August 2024
Page 5 of 5 of this archive, newest first.
What a 25% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
VendorInvestigate result on a Tianjin tirzepatide lot lands 0.7 points below the supplier’s figure
The report states the gradient, the wavelength and the integration threshold, which is more than most.
What happens when the drug is taken away: three randomised answers
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
The badge economy, and what it is actually certifying
The Journal does not treat a badge as evidence and states so wherever it reports one.
Gauge, pain and flow rate
Gauge affects pain and flow rate rather than depth. A finer needle is more comfortable and slower, and with a viscous solution the difference is noticeable.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
France pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Wuxi export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
India declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.